How to access Rinvoq from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient with moderate-to-severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, or axial spondyloarthritis may receive a prescription for Rinvoq (upadacitinib) from their treating rheumatologist, dermatologist, or gastroenterologist. Rinvoq is FDA-approved in the United States and manufactured by AbbVie. It is an oral, once-daily selective JAK1 inhibitor used after inadequate response to conventional or biologic therapy. Local access in the UAE varies by indication and by emirate, and specific strengths can be out of stock at particular hospital pharmacies. When that happens, a named-patient import pathway through the Ministry of Health and Prevention (MoHAP) remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains that pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.
The clinical situation
Rinvoq is an oral JAK1-selective small molecule taken once daily. Dosing is indication-specific: 15 mg daily is typical for rheumatoid and psoriatic arthritis; 15 mg or 30 mg for atopic dermatitis; 45 mg induction then 15 mg or 30 mg maintenance for ulcerative colitis and Crohn's disease. Baseline workup per FDA labeling includes tuberculosis screening, hepatitis B and C serology, lipid panel, CBC with differential, and liver function tests. The FDA boxed warning on the JAK class covers serious infections, malignancy, major adverse cardiovascular events, thrombosis, and mortality in certain rheumatoid arthritis populations over age 50 with at least one cardiovascular risk factor. Your physician will walk through cardiovascular and malignancy risk before starting therapy and schedule ongoing monitoring.
Is Rinvoq legally importable into the UAE?
Yes — through the MoHAP named-patient / personal-use import framework, coordinated with the treating facility's pharmacy. The UAE has a mature pathway for specialty medicines that are approved by reference authorities but not stocked or registered for the specific indication locally.
The MoHAP named-patient route allows a UAE-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority such as the US FDA or EMA, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering pharmacy. Dubai Health Authority and Department of Health Abu Dhabi issue complementary approvals where the dispensing facility sits inside their jurisdiction.
How the pathway works, step by step
- Consultation with your treating physician. The prescribing decision is clinical. Your physician documents the indication, severity, prior therapies, and rationale for Rinvoq.
- Baseline screening. TB, viral hepatitis, lipid panel, and relevant vaccination status are confirmed and documented.
- MoHAP named-patient application. Your physician or the hospital's pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from AbbVie's authorised distribution under DSCSA chain-of-custody.
- Shipment. Rinvoq is an oral tablet with standard room-temperature storage (up to 30 degrees Celsius); shipment moves with tamper-evident packaging and tracking documentation.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription and your physician initiates therapy on schedule.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis, severity scoring (DAS-28, EASI, Mayo score, or equivalent), prior therapy history, and Rinvoq as the indicated next step
- Verification of their UAE medical licence (MoHAP / DHA / DoH)
- A patient identifier (an anonymised reference is usually preferred for privacy)
- Documented pre-treatment screening (TB, hepatitis, lipids, CBC, LFTs) consistent with FDA labeling
- The planned dosing strength and refill cadence
- A discussion note on JAK-class cardiovascular and malignancy risk appropriate for the patient profile
Reserve Meds provides a physician documentation kit that bundles the templates MoHAP reviewers expect to see for JAK-class therapies, including the cardiovascular and malignancy risk-benefit discussion the class requires.
Typical costs and indicative timing
Reserve Meds gives you a drug-only reference range plus a transparent delivered quote at intake. As an illustrative composite case, the US cash-pay reference range for a 30-tablet month supply of Rinvoq 15 mg sits in an indicative 2026 band of roughly USD 6,500 to 7,500. Higher strengths cost more. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost, and the delivered quote we issue at intake shows each line separately so nothing is hidden.
Indicative timing — not a guarantee — for first dose after cohort intake opens is approximately 7 to 14 days from the moment a complete application is submitted to MoHAP, assuming the documentation package is clean on first pass. Refills ship on a rolling cadence thereafter.
Reserve Meds is in pre-launch; service availability is limited to our first cohort. All timelines are indicative, not guarantees. If your clinical situation is time-sensitive, flag that when you join the waitlist and we will triage accordingly.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Rinvoq specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for MoHAP / DHA / DoH review.
- Logistics. Tamper-evident, internationally tracked shipment to your named dispensing pharmacy.
- Concierge case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician, and dispensing sits with the licensed UAE pharmacy of record.
FAQ
Is this legal in the UAE?
Yes, when executed through the MoHAP named-patient / personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across immunology, oncology, and rare disease.
What about the JAK boxed warning?
The FDA boxed warning on JAK inhibitors covers serious infections, malignancy, major adverse cardiovascular events, and thrombosis. Your physician performs a risk-benefit assessment before starting therapy and monitors per labeling. Reserve Meds does not make that clinical judgement — your physician does.
Can a locally registered JAK work instead?
If a locally registered JAK is clinically appropriate for your case, your physician will consider it. The named-patient pathway is relevant where Rinvoq specifically is indicated for your indication, strength, or supply gap, and the rationale is documented.
What if my physician has not filed a MoHAP named-patient request before?
Named-patient import is an institutional process your hospital will have encountered. Our documentation kit is written for first-time applicants and tracks what reviewers typically ask for.
Will private insurance cover this?
Cash-pay is the default posture. Some UAE private insurers reimburse named-patient imports on a case-by-case basis; we supply documentation so you or your hospital can submit, but we do not process insurance claims directly.
Join the waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Rinvoq coordination in the UAE.
Add me to the Rinvoq waitlistThis guide is educational, not medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician.